The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids

• Published in: Journal of Antimicrobial Chemotherapy 2021-09, Vol.76 (10), p.2690-2696
• Main Authors: Kuno, Toshiki, Miyamoto, Yoshihisa, Iwagami, Masao, Ishimaru, Miho, Takahashi, Mai, Egorova, Natalia N
• Format: Article
• Language: English
• Subjects: Adenosine Monophosphate - analogs & derivatives; Alanine - analogs & derivatives; Antiviral Agents - therapeutic use; COVID-19 - drug therapy; Humans; Original Research; Retrospective Studies; SARS-CoV-2; Steroids
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkab256

Background Remdesivir has been shown to decrease SARS-CoV-2 viral loads and the duration of COVID-19 symptoms. However, current evidence regarding the association between remdesivir and in-hospital mortality for patients with COVID-19 steroid treatments is limited. We aimed to investigate whether remdesivir reduces in-hospital mortality among patients with COVID-19 treated with steroids. Methods In this retrospective multicentre study, we reviewed the medical records of 3372 patients discharged between 1 March 2020 and 30 March 2021, with laboratory confirmed COVID-19 in the Mount Sinai Health System and treated with steroids. We evaluated the effect of remdesivir on the outcomes using propensity score analyses. Subgroup analyses were conducted by stratification of patients by endotracheal intubation and COVID-19 antibody status. Acute kidney injury (AKI) was defined as an absolute serum creatinine increase of 0.3 mg/dL or a relative increase of 50%. Results Of the 3372 eligible patients, 1336 (39.6%) received remdesivir. After 1:1 propensity score matching (N = 999 pairs), in-hospital mortality was similar between those with and without remdesivir (21.4% versus 21.6%, respectively, P = 0.96). Remdesivir was not significantly associated with in-hospital mortality regardless of endotracheal intubation or COVID-19 antibody status. However, there was a signal that remdesivir was associated with a reduced risk of AKI in the propensity matched analysis (17.5% versus 23.4%, respectively, P = 0.001). Conclusions Remdesivir was not associated with reduced risk of in-hospital mortality in patients with COVID-19 treated with steroids but potentially associated with decreased risk of AKI. These findings should be confirmed in prospective studies focusing on COVID-19 patients treated with steroids.